- Home
- PMO vs EDIT Comparison
PMO vs EDIT Comparison
Compare PMO & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PMO | EDIT |
|---|---|---|
| Founded | 1993 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 291.4M | 233.3M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | PMO | EDIT |
|---|---|---|
| Price | $10.56 | $2.43 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $4.13 |
| AVG Volume (30 Days) | 99.0K | ★ 1.7M |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 4.10% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.42 | N/A |
| Revenue | N/A | ★ $46,383,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $24.38 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.57 | $0.91 |
| 52 Week High | $10.68 | $4.54 |
Technical Indicators
Market Signals| Indicator | PMO | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 71.79 | 42.37 |
| Support Level | $10.31 | $2.09 |
| Resistance Level | $10.58 | $2.55 |
| Average True Range (ATR) | 0.07 | 0.17 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 94.12 | 51.56 |
Price Performance
Historical ComparisonAbout PMO Putnam Municipal Opportunities Trust
Putnam Municipal Opportunities Trust is a non-diversified closed-end management investment company. It seeks to provide as high a level of current income free from federal income tax as Putnam Management believes is consistent with the preservation of capital. The fund invests in healthcare, utilities, transportation, tax bonds, local debt, state debt, and education.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.